Rosiglitazone

The main ingredient of this product is rosiglitazone.

Interactions with other drugs and other forms of interactions 1. Drugs metabolized by cytochrome P450: In vitro drug metabolism tests have shown that rosiglitazone does not inhibit major P450 at clinically used doses. In vitro test data confirm that rosiglitazone is mainly metabolized by CYP2C8, and a very small part is metabolized by CYP2C9. 2. Nimodipine and oral contraceptives (ethinyl estradiol and norethindrone) are mainly metabolized by the CYP3A4 pathway, so the combination of nimodipine (4 mg, twice a day) with this product will not have a clinically significant pharmacokinetic effect on the above two drugs. 3. Glyburide: For diabetic patients whose condition is stable after taking glyburide, the combination of this product (2 mg/time, twice a day) with glyburide (3.75 mg/day to 10 mg/day) for 7 days will not change their 24-hour average steady-state blood glucose level. 4. Metformin: For healthy subjects, the co-administration of this product (2 mg/time, twice daily) and metformin (500 mg/time, twice daily) for 4 days will not change the steady-state pharmacokinetic parameters of this product and metformin. 5. Acarbose: Healthy subjects took acarbose (100 mg/time, 3 times a day) for 7 days, which had no effect on the pharmacokinetic parameters of a single oral dose of this product. 6. Digoxin: Healthy subjects took this product (8 mg/time, once a day) for 14 days, which had no effect on the steady-state pharmacokinetic parameters of digoxin (0.375 mg/time, once a day). 7. Warfarin: Continuous use of this product has no effect on the steady-state pharmacokinetic parameters of warfarin enantiomers. 8. Ethanol: Drinking a moderate amount of ethanol once does not increase the risk of acute hypoglycemia in patients with type 2 diabetes taking this product. 9. Ranitidine: Ranitidine (150 mg/time, twice daily) was administered to healthy subjects for 4 days, which did not change the pharmacokinetic parameters of rosiglitazone administered orally or intravenously. This result indicates that the increase in gastrointestinal pH does not affect the oral absorption of this product. 10. Contraindications: No known contraindications.

Chemical name: (±)-5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (Z)-2-butenedioate. Molecular formula: C18H19N3O3S·C4H4O4 Molecular weight: 473.52

1. There is no clinical interaction with nifedipine, oral contraceptives (ethinyl estradiol, norethindrone) and other drugs metabolized by CYP3A4. 2. When used in combination with glibenclamide, metformin or acarbose, it has no effect on the steady-state pharmacokinetics and clinical efficacy of these drugs. 3. It does not affect the metabolism and clinical treatment of digoxin, warfarin, ethanol, ranitidine, etc. in the body. 4. When used in combination with sulfonylureas, it does not significantly increase the frequency of hypoglycemia caused by the latter. 5. When used in combination with metformin, it does not increase the incidence of gastrointestinal reactions of the latter and does not increase plasma lactate concentration.